- •
Direct-acting antivirals (DAAs) have become standard treatment of HCV genotype 1 infection.
- •
For many treatment regimens, the duration is just 12 weeks.
- •
Ribavirin may provide additional efficacy for patients with cirrhosis or HCV subtype 1a infection.
- •
The continued rapid development of DAAs suggests that new regimens will become available for shorter duration of therapy.
Current and Evolving Treatments of Genotype 1 Hepatitis C Virus
Section snippets
Key points
Goal of therapy
The aim of treating HCV infection is to cure the chronic viral infection, thereby preventing complications of HCV-related liver disease, including cirrhosis, hepatocellular carcinoma (HCC), and the need for a liver transplant. Cure from HCV infection can be measured by SVR,13, 14 which is defined as the absence of HCV RNA by polymerase chain reaction after cessation of antiviral therapy. Classically, SVR was measured 24 weeks after stopping therapy, but the FDA has accepted the absence of HCV
Patient evaluation overview
Routine laboratory evaluation and assessment of the degree of fibrosis, mostly by noninvasive measures, are extremely important to prioritize patients for treatment and to determine the appropriate treatment regimen and duration. According to the HCV guidance from the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA), patients with advanced fibrosis, cirrhosis, or with extrahepatic complications of HCV have priority for treatment compared
Treatment options
The current HCV treatment guidelines from a joint collaboration of the AASLD, IDSA, and International Antiviral Society USA (IAS-USA)17 and from the European Association for the Study of the Liver16 include later-generation DAAs in their recommendations for treatment of genotype 1 infection. Summarized versions of these guidelines can be seen in Table 2, Table 3, Table 4. Updated and detailed versions of the guidelines should be accessed on their respective Web pages (//www.HCVguidelines.org
Drug interactions
A summary of drug interactions from the AASLD/IDSA/IAS-USA guidelines17 is presented in Table 6.
Monitoring during therapy
Response guided therapy, which was standard of care for interferon-based regimens, is not applicable with all-oral treatment regimens for HCV genotype 1 infection. All-oral treatments of HCV genotype 1 infection are highly effective; data from clinical trials indicate that in 95% to 100% of patients with HCV genotype 1 infection, HCV RNA becomes undetectable during treatment. Virologic failure because of drug resistance is extremely rare. Patients who do not achieve SVR usually experience
Safety of direct-acting antivirals
As interferon-based regimens become less common, the complications due to treatment have decreased, and tolerance of current all-oral regimens is excellent.48 However, ribavirin is associated with adverse hematologic events, fatigue, rash, sinusitis, and gout.49 Ribavirin is also contraindicated for patients with a history of significant cardiac disease and in women who are pregnant because of significant teratogenic and embryocidal effects.50 That said, even with ribavirin included, all-oral,
Future therapy
Several novel DAAs for HCV are in clinical development, making it likely that treatment outcomes for patients with genotype 1 HCV infection will continue to improve.
In the C-WORTHY phase 2 study, HCV genotype 1–infected treatment-naive patients with cirrhosis (cohort 1) and treatment-experienced patients without cirrhosis (cohort 2) received 12 or 18 weeks of grazoprevir (NS3/4A protease inhibitor) and elbasvir (an NS5A inhibitor) with or without ribavirin. SVR12 rates ranged from 90% (28 of
Summary
In the past 2 years, the HCV therapeutic landscape has shifted from difficult-to-tolerate regimens with low rates of response to shorter, better-tolerated, all-oral regimens with rates of SVR greater than 95%. As more DAAs are approved for use in patients, the focus for future clinical trials will be on treating various patient populations, such patients with advanced fibrosis, post–liver transplant patients, and patients with kidney disease.
References (57)
- et al.
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon
J Hepatol
(1996) - et al.
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
Lancet Infect Dis
(2013) - et al.
Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-symmetric inhibitors with diyne and biphenyl linkers
Bioorg Med Chem Lett
(2015) - et al.
Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b
Bioorg Med Chem Lett
(2015) - et al.
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
Lancet
(2013) - et al.
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study
Lancet
(2014) - et al.
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection
Gastroenterology
(2014) - et al.
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)
Lancet Infect Dis
(2015) - et al.
1425 Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment naïve patients: results from QUEST-1, a phase III trial
J Hepatol
(2013) - et al.
1413 Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment naïve patients: results from QUEST-2, a phase III trial
J Hepatol
(2013)
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection
Gastroenterology
Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis
Clin Gastroenterol Hepatol
What is the future of ribavirin therapy for hepatitis C?
Antivir Res
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
Lancet
Diagnosis, management, and treatment of hepatitis C: an update
Hepatology
Psychiatric clearance for patients started on interferon-alpha-based therapies
Am J Psychiatry
Telaprevir for previously untreated chronic hepatitis C virus infection
N Engl J Med
Boceprevir for untreated chronic HCV genotype 1 infection
N Engl J Med
Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial
Antivir Ther
Sofosbuvir for previously untreated chronic hepatitis C infection
N Engl J Med
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
N Engl J Med
The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach
Curr Pharm Des
Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy
Aliment Pharmacol Ther
Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies
Gastroenterology
EASL recommendations on treatment of hepatitis C 2015
J Hepatol
Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with metavir F0-2: COSMOS study subgroup analysis
Gastroenterol Hepatol (N Y)
Cited by (16)
Information and consensus document for the detection and management of chronic kidney disease
2022, NefrologiaCitation Excerpt :Treatments based on interferon and ribavirin have been poorly tolerated as they are eliminated by the kidney and have significant side effects, with a low rate of sustained viral response. Direct-acting antivirals achieve a sustained viral response greater than 90-95%, presenting an excellent safety and tolerance profile.148–150 Adverse effects are infrequent, but and interactions with commonly used drugs are very common, to be taken into account especially in renal transplant recipients.151
Landscape of Kidney Transplantation in Patients With Compensated Liver Disease: Results of a Survey of Transplant Surgeons in the United States
2016, Transplantation ProceedingsCitation Excerpt :In addition, major progress has been made during the last 10 years in the treatment of HBV and HCV infections. The new direct antiviral therapies cure HCV infection in more than 90% of patients with liver cirrhosis and potentially result in regression of fibrosis [12]. It is clear that persistent infection with HCV and HBV is a major risk for the development of hepatocellular carcinoma (HCC) [13].
Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland
2020, Journal of Viral HepatitisExcess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals
2020, Journal of General Internal Medicine
Potential Conflict of Interest: The authors consults for and received grants from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck.